Role of the Vitamin D System in the Pathogenesis of Renal Osteodystrophy

Vitamin D ◽  
1984 ◽  
pp. 611-639 ◽  
Author(s):  
James T. McCarthy ◽  
Rajiv Kumar
1983 ◽  
Vol 3 (1_suppl) ◽  
pp. 24-26 ◽  
Author(s):  
Francisco Llach

It seems that CAPD may improve some patients with osteomalacia but may be similar to hemodialysis in regard to osteitis fibrosa. However, long-term prospective evaluation of the incidence of bone disease in CAPD patients is necessary before we can determine how CAPD may alter the incidence and expression of renal osteodystrophy. We need more information before we can conclude that CAPD may improve pure osteomalacia. Finally, the data available are insufficient to clarify the role of vitamin D analogues in these patients.


1986 ◽  
Vol 7 (4) ◽  
pp. 275-284 ◽  
Author(s):  
Russell W. Chesney ◽  
Otto Mehls ◽  
Constantine S. Anast ◽  
Edward Brown ◽  
Marc R. Hammerman ◽  
...  

Author(s):  
Daniela Menichini ◽  
Gianpiero Forte ◽  
Beatrice Orrù ◽  
Giuseppe Gullo ◽  
Vittorio Unfer ◽  
...  

Abstract. Vitamin D is a secosteroid hormone that plays a pivotal role in several metabolic and reproductive pathways in humans. Increasing evidence supports the role of vitamin D deficiency in metabolic disturbances and infertility in women with polycystic ovary syndrome (PCOS). Indeed, supplementation with vitamin D seems to have a beneficial role on insulin resistance and endometrial receptivity. On the other hand, exceedingly high levels of vitamin D appear to play a detrimental role on oocytes development and embryo quality. In the current review, we summarize the available evidence about the topic, aiming to suggest the best supplementation strategy in women with PCOS or, more generally, in those with metabolic disturbances and infertility. Based on the retrieved data, vitamin D seems to have a beneficial role on IR, insulin sensitivity and endometrial receptivity, but high levels and incorrect timing of administration seem to have a detrimental role on oocytes development and embryo quality. Therefore, we encourage a low dose supplementation (400–800 IU/day) particularly in vitamin D deficient women that present metabolic disturbances like PCOS. As far as the reproductive health, we advise vitamin D supplementation in selected populations, only during specific moments of the ovarian cycle, to support the luteal phase. However, ambiguities about dosage and timing of the supplementation still emerge from the clinical studies published to date and further studies are required.


Author(s):  
Sunghwan SUH ◽  
Park Mi Kyoung ◽  
Kim Duk Kyu ◽  
Kyoungjune Pak
Keyword(s):  

Author(s):  
Giovanni Damiani ◽  
Rosalynn Conic ◽  
Gloria Orlando ◽  
Anna Zampetti ◽  
Elena Marinello ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document